Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 2.62
MYOS's Cash to Debt is ranked higher than
57% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. MYOS: 2.62 )
Ranked among companies with meaningful Cash to Debt only.
MYOS' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: 10000.00 Max: No Debt
Current: 2.62
Equity to Asset 0.79
MYOS's Equity to Asset is ranked higher than
76% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MYOS: 0.79 )
Ranked among companies with meaningful Equity to Asset only.
MYOS' s Equity to Asset Range Over the Past 10 Years
Min: 0.17  Med: 0.87 Max: 0.96
Current: 0.79
0.17
0.96
F-Score: 3
Z-Score: -5.28
M-Score: 4.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3979.26
MYOS's Operating margin (%) is ranked lower than
97% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.51 vs. MYOS: -3979.26 )
Ranked among companies with meaningful Operating margin (%) only.
MYOS' s Operating margin (%) Range Over the Past 10 Years
Min: -4642.42  Med: -244.25 Max: -128.6
Current: -3979.26
-4642.42
-128.6
Net-margin (%) -3437.04
MYOS's Net-margin (%) is ranked lower than
97% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.44 vs. MYOS: -3437.04 )
Ranked among companies with meaningful Net-margin (%) only.
MYOS' s Net-margin (%) Range Over the Past 10 Years
Min: -5653.54  Med: -281.28 Max: -128.48
Current: -3437.04
-5653.54
-128.48
ROE (%) -82.49
MYOS's ROE (%) is ranked lower than
93% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. MYOS: -82.49 )
Ranked among companies with meaningful ROE (%) only.
MYOS' s ROE (%) Range Over the Past 10 Years
Min: -2665.24  Med: -117.33 Max: -88.51
Current: -82.49
-2665.24
-88.51
ROA (%) -70.54
MYOS's ROA (%) is ranked lower than
94% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. MYOS: -70.54 )
Ranked among companies with meaningful ROA (%) only.
MYOS' s ROA (%) Range Over the Past 10 Years
Min: -2600  Med: -83.05 Max: -45
Current: -70.54
-2600
-45
ROC (Joel Greenblatt) (%) -177.72
MYOS's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.81 vs. MYOS: -177.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYOS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -371466.67  Med: -1386.73 Max: -251.9
Current: -177.72
-371466.67
-251.9
Revenue Growth (3Y)(%) 144.50
MYOS's Revenue Growth (3Y)(%) is ranked higher than
99% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MYOS: 144.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYOS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 144.5
Current: 144.5
0
144.5
EBITDA Growth (3Y)(%) -26.80
MYOS's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. MYOS: -26.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYOS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -37  Med: 245.50 Max: 509.1
Current: -26.8
-37
509.1
EPS Growth (3Y)(%) -29.90
MYOS's EPS Growth (3Y)(%) is ranked lower than
85% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. MYOS: -29.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYOS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.8  Med: 276.00 Max: 531.7
Current: -29.9
-39.8
531.7
» MYOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MYOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.08
MYOS's P/B is ranked higher than
86% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.50 vs. MYOS: 1.08 )
Ranked among companies with meaningful P/B only.
MYOS' s P/B Range Over the Past 10 Years
Min: 0.92  Med: 3.85 Max: 16.26
Current: 1.08
0.92
16.26
P/S 34.63
MYOS's P/S is ranked lower than
99.99% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. MYOS: 34.63 )
Ranked among companies with meaningful P/S only.
MYOS' s P/S Range Over the Past 10 Years
Min: 4.13  Med: 15.58 Max: 500
Current: 34.63
4.13
500
Current Ratio 3.34
MYOS's Current Ratio is ranked higher than
66% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. MYOS: 3.34 )
Ranked among companies with meaningful Current Ratio only.
MYOS' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 3.88 Max: 27.24
Current: 3.34
0.03
27.24
Quick Ratio 1.70
MYOS's Quick Ratio is ranked higher than
51% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. MYOS: 1.70 )
Ranked among companies with meaningful Quick Ratio only.
MYOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 2.76 Max: 26.31
Current: 1.7
0.03
26.31
Days Inventory 1.00
MYOS's Days Inventory is ranked higher than
99% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.42 vs. MYOS: 1.00 )
Ranked among companies with meaningful Days Inventory only.
MYOS' s Days Inventory Range Over the Past 10 Years
Min: 43.2  Med: 204.36 Max: 1919.9
Current: 1
43.2
1919.9
Days Sales Outstanding 1.00
MYOS's Days Sales Outstanding is ranked higher than
99% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.67 vs. MYOS: 1.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.36  Med: 75.90 Max: 107.22
Current: 1
66.36
107.22
Days Payable 146.64
MYOS's Days Payable is ranked higher than
81% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. MYOS: 146.64 )
Ranked among companies with meaningful Days Payable only.
MYOS' s Days Payable Range Over the Past 10 Years
Min: 20.31  Med: 44.16 Max: 970.9
Current: 146.64
20.31
970.9

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 2.01
MYOS's Price/Net Current Asset Value is ranked higher than
89% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.77 vs. MYOS: 2.01 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MYOS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.37  Med: 6.33 Max: 80.17
Current: 2.01
3.37
80.17
Price/Tangible Book 1.80
MYOS's Price/Tangible Book is ranked higher than
77% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.88 vs. MYOS: 1.80 )
Ranked among companies with meaningful Price/Tangible Book only.
MYOS' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.11  Med: 6.01 Max: 80.17
Current: 1.8
3.11
80.17
Price/Median PS Value 2.40
MYOS's Price/Median PS Value is ranked lower than
85% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. MYOS: 2.40 )
Ranked among companies with meaningful Price/Median PS Value only.
MYOS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 0.88 Max: 25.81
Current: 2.4
0.32
25.81
Earnings Yield (Greenblatt) (%) -120.09
MYOS's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 720 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MYOS: -120.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYOS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -152.71  Med: 181.10 Max: 74436.8
Current: -120.09
-152.71
74436.8

More Statistics

Revenue(Mil) $0
EPS $ -1.48
Beta-0.19
Short Percentage of Float1.77%
52-Week Range $1.34 - 7.50
Shares Outstanding(Mil)3.32

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
MYOS Corp was incorporated in the State of Nevada on April 11, 2007. The Company is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue. In February 2011, the Company acquired its platform dietary supplement product called MYO-T12. Its trademark includes FORTETROPIN. Its competition includes numerous nutritional supplement companies that are fragmented in terms of geographic market coverage, distribution channels and product categories.
» More Articles for MYOS

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events Feb 04 2016
MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Dec 22 2015
MYOS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Dec 21 2015
Why Are These Stocks Gaining Ground on Thursday? Dec 17 2015
4 Stocks Under $10 That Need To Be Watched Today Dec 17 2015
MYOS Corporation Announces Strategic Investment by RENS Technology Inc. Dec 17 2015
MYOS Corporation Announces Strategic Investment by RENS Technology Inc. Dec 17 2015
MYOS CORP Financials Dec 08 2015
MYOS CORP Files SEC form 8-K, Other Events Nov 30 2015
MYOS CORP Files SEC form 10-Q, Quarterly Report Nov 16 2015
MYOS Corp. – Value Analysis (NASDAQ:MYOS) : November 3, 2015 Nov 03 2015
Maintaining Muscle Linked to Preserving Healthy Brain Tissue Oct 26 2015
Maintaining Muscle Linked to Preserving Healthy Brain Tissue Oct 26 2015
MYOS' Proprietary Muscle Building Technology Fortetropin: Foundation for New Dietary Recommendations Oct 19 2015
MYOS' Proprietary Muscle Building Technology Fortetropin: Foundation for New Dietary Recommendations Oct 19 2015
MYOS Corp. Earnings Q2, 2015 Oct 02 2015
Cryoport Appoints Robert Hariri, MD, PhD to its Board of Directors Oct 01 2015
MYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers Aug 20 2015
MYOS CORP Files SEC form 10-Q, Quarterly Report Aug 14 2015
MYOS Corporation to Host Conference Call to Discuss Management Highlights Aug 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK